Luteinizing hormone-releasing hormone analogue: Leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation

Bone Marrow Transplantation

Volumn 21, Issue 8, 1998, Pages 821-823

  Chiusolo, P ^a   Salutari, P ^a   Sica, S ^a   Scirpa, P ^a   Laurenti, L ^a   Piccirillo, N ^a   Leone, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Leuprorelin; LHRH analogue; Menstrual bleeding; Stem cell transplantation

Indexed keywords

ESTRADIOL; ESTROGEN; FOLLITROPIN; GESTAGEN; GONADORELIN DERIVATIVE; LEUPRORELIN; LUTEINIZING HORMONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; BLOOD DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GONAD FUNCTION; HEMOSTASIS; HODGKIN DISEASE; HORMONE SUBSTITUTION; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MENOPAUSE; MENSTRUATION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PREMENOPAUSE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; UTERUS BLEEDING;

EID: 0031897519     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701187     Document Type: Article

References (16)

1. Samsioe G. Coagulation and anticoagulation effects of contraceptives steroids. Am J Obstet Gynecol 1994; 70: 1523-1530.
2. Lindgren S, Olsson R. Liver damage from low-dose oral contraceptives. J Intern Med 1993; 234: 287-290.
3. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thromboses. Blood 1996; 88: 3698-3703.
4. Fegan C, Poynton CH, Whittaker JA. The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplant 1990; 5: 373-377.
5. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previous unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
6. Corbin A, Bex FJ. Reproductive pharmacology of LHRH and agonists in female and males. Acta Eur Fertil 1980; 11: 113-130.
7. Winkler U, Buhler K, Koslowski S et al. Plasmatic hemostasis in gonadotrophin releasing hormone analogue therapy: effect of leuprorelin acetate depot on coagulation and fibrinolytic activities. Clin Ther 1992; 14 (Suppl. A): 114-120.
8. Fogelman I. Gonadototropin-releasing hormone agonist and the skeleton. Fertil Steril 1992; 57: 714-724.
9. Ghalie R, Porter C, Radwanska E et al. Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation. Am J Hematol 1993; 42: 350-352.
10. Laufer MR, Towsend NL, Parsons KE et al. The use of leuprolide acetate for the induction of amenorrhea in woman undergoing bone marrow transplantation (BMT): a pilot study. Proc ASCO 1995; 14: 526 (Abstr. 1732).
11. Brault P, Lhomme C, Bourhuis JH et al. Prevention of menstruation with leuprorelin (GnRh agonist) in pre-menopausal women undergoing aplastic chemotherapy for hematological malignancies. Bone Marrow Transplant 1997; 19 (Suppl. 1) S133 (Abstr. 530).
12. Sica S, Salutari P, Di Mario A et al. Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis. Am J Hematol 1996; 51: 248-249.
13. Friedman AJ, Daly M, Juneau-Norcross M, Rein MS. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin releasing-hormone agonist. Fertil Steril 1992; 58: 413-415.
14. Friedman AJ, Barbieri RL, Benacerraf BR, Schiff I. Treatment of leyomiomata with intranasal or subcutaneous leuprolide, a gonadotropin releasing-hormone agonist. Fertil Steril 1987; 48: 560-564.
15. Kreuser ED, Klingmuller D, Thiel E. The role of LHRH analogues in protecting gonadal functions during chemotherapy and irradiation. Eur Urol 1993; 23: 157-164.
16. Sanders JE, Hawley, J, Levy W et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total body irradiation and bone marrow transplantation. Blood 1996; 87: 3045-3052.